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Abstract 
 Stem cell reserves diminish with aging and we no longer effectively heal, with chronic illness being the result. 
With adequate numbers of stem cells the body is expected to heal naturally. Here we provide information and 
reference to both patients and doctors on therapeutic use of stem cells, treatment centers around the world, 
addresses, contact persons, treatment cost, and sources of stem cells used, type of conditions being treated and 
the protocols used. The treatment centers were directly contacted through email, phone call or through their web 
page. 11 treatment centers responded from 8 different countries with 4 in the USA alone, 4 treatment centers 
recommended by the Repair Stem Cell Institute which is the biggest patient advocate. Most treatment centers 
are outside the USA because of strict stem cell treatment regulatory laws within the USA. All the 11 Treatment 
Centers that responded were able to provide their contact details, source of Stem Cells being used and medical 
conditions being treated. Such information will provide good guidance to both Physicians and patients who want 
to consider Stem Cell Treatment. It is hoped that more stem cell treatment centers will be reported about in the 
next publication as therapeutic stem cell regulatory laws become less strict especially in the USA. 
Keywords: Pluripotent; Embryonic Stem Cells; Fetal Stem Cells; Adult Stem Cells; Mesenchymal Stem Cells; 
Hematopoietic Stem Cells. 
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1. Introduction  
A stem cell is a kind of undifferentiated cell that has a unique capacity to renew itself and to give rise to 
specialized cell types of a different tissue. Although most cells of the body such as heart cells or skin cells are 
committed to conduct a specific function, a stem cell is uncommitted and remains uncommitted, until it receives 
a signal to develop into a specialized cell. Researchers have for years looked for ways to use stem cells for 
therapeutic possibilities to replace cells and tissues that are damaged or diseased. This research has yielded a 
glimpse at a class of stem cells that can develop into any cell type in the body. This class of stem cells is called 
pluripotent, meaning the cells have the potential to renew themselves, differentiate and develop to almost all of 
the more than 200 different known cell types, stem cells with this unique property come from embryos and fetal 
tissue. 
In 1998, investigators were able to isolate this class of pluripotent stem cell from early human embryos and 
grew them in culture, they may have the potential to generate replacement cells for a broad array of tissues and 
organs such as the heart, pancreas and the nervous system. This class of human stem cells hold the promise in 
regenerative medicine of being able to repair or replace cells or tissues that are damaged or destroyed by many 
of devastating diseases and disability.  
A stem cell from the embryo, fetus or adult that has under certain conditions has the ability to reproduce itself 
for longer periods or in the case of adult stem cells, throughout the life of the organism.  
1.1 Embryonic Stem Cells 
An embryonic stem cell is derived from a group of cells called the inner cell mass, which is part of the early (4 
to 5 days) embryo development called the blastocyst stage. Once removed from the blastocyst, the cells of the 
inner cell mass can be cultured to produce embryonic cells. These embryonic stem cells are not themselves 
embryos. Evidence is emerging that these cells do not behave in the laboratory as they would in the developing 
embryo.                          
1.2 Adult Stem Cells 
An adult stem cell is thought to be an undifferentiated (unspecialized) cell that occurs in a differentiated 
(specialized) tissue or organ that can renew itself, and become specialized to yield all of the specialized cell 
types of the tissue or organ from which it originated. Adult stem cells are capable of making identical copies of 
themselves for the lifetime of the organism. This property is referred to as ‘’self renewal’’ Adult stem cells 
usually divide to generate progenitor or precursor cells, which then differentiate or develop into mature cell 
types that have characteristic shapes and specialized functions, e.g., muscle contraction or nerve cell signaling. 
Sources of adult stem cells include bone marrow, blood, the cornea and the retina of the eye, brain, skeletal 
muscle, dental pulp, liver, skin, the lining of the gastrointerstinal tract, and pancreas. 
The most abundant information about adult human stem cells come from studies of hematopoietic stem cells 
isolated from the bone marrow and blood. These adult stem cells have been extensively studied and applied 
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therapeutically for various diseases. 
1.3 Stem Cell Transplantation Research 
Stem cells may hold the key to replacing cells lost in many devastating diseases. Some diseases included in stem 
cell research include Parkinson’s disease, diabetes, chronic heart disease, end-stage kidney disease, liver failure, 
and cancer, these are just a few for which stem cells have therapeutic potential. The goal is to find a way to 
replace what natural processes have taken way. Science has brought us to a point where the immune response 
can be subdued, so that organs from one person can be used to replace the diseased organs and tissues of 
another. But, despite recent advances in transplantation sciences, there is a shortage of donor organs that makes 
it unlikely that the growing demand for lifesaving organ replacements will be fully met through organ donation 
strategies. 
 
Figure 1: An example of Adipose Tissue Stem Cells in culture for therapeutic use 
The use of stem cells to generate replacement tissues for treating neurological diseases is a major focus of 
research. Spinal cord injury, multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease are among those 
diseases for which the concept of replacing destroyed and dysfunctional cells in the brain or spinal cord is a 
practical goal. 
Another major discovery frontier for research on adult and embryonic stem cells is the development of 
transplantable pancreatic tissue that can be used to treat diabetes. Researchers have recently shown that human 
embryonic stem cells to be directly differentiated into cells that produce insulin. The lines of unaltered human 
embryonic stem cells that exist will not be suitable for direct use in patients. These cells will need to be 
differentiated or otherwise modified before they can be used clinically. Current challenges are to direct the 
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differentiation of embryonic stem cells into specialized cell populations and also to devise ways to control their 
development or proliferation once placed in patients.                                                        
Embryonic stem cells will undoubtedly be key as research tools for understanding fundamental events in 
embryonic development that one day may explain the causes of birth defects and approaches to correct or 
prevent them. Another important area of research that links developmental biology and stem cell biology is 
understanding genes and molecules, such as growth factors and nutrients, that function during the development 
of the embryo so that they can be used for growing stem cells in the laboratory and direct their development into 
specialized cell types. 
1.4 Stem Cells as Therapeutic Delivery System 
Stem cells are already being explored as a vehicle for delivering genes to specific tissues in the body. Stem cells 
based therapies are a major area of investigation in cancer research. For many years, restoration of blood and 
immune system function has been used as a component in the care of cancer patients who have been treated with 
chemotherapeutic agents. Now researchers are trying to devise more ways to use specialized cells derived from 
stem cells to target specific cancerous cells and directly deliver treatments that will destroy or modify them as 
seen in figure 2 below. 
 
Figure 2: A schematic diagram of one type of stem cell therapy procedure. 
1.5 The Purpose for this publication 
The new discovery of healing systems within the body opens up a whole new vision for treating diseases. We all 
have a banking facility for autologous stem cells within our bodies, in our bone marrow, fat and other areas. 
These cells are called upon to heal injuries or debilitating diseases. As we age, the reserves of stem cells within 
our bone marrow and fat begin to diminish. When we do not have enough stem cells to address illnesses or 
injury, symptoms occur, and we no longer effectively heal with chronic illness being the result. The process of 
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extracting stem cells from the bone marrow or fat and re-introducing them in adequate numbers into the body 
allows the body to heal as it is meant to, naturally. 
Most countries of the world look up to the United States of America (USA) as a pace setter for all things, could 
it be democracy, human rights, technology, health ethics etc. This directly means that if for some reason, the 
USA does not allow certain procedures to be practiced in the US, most countries will not feel comfortable 
practicing those in their own countries. This is exactly what has happened with the use of stem cells in therapy, 
regardless of so many research studies showing that the use of stem cells in therapy is safe and effective (adult 
stem cells), the Food and Drug Administration (FDA) has from time and time again denied Scientist and 
Doctors in America to legally use adult stem cells as means for curing a wide variety of diseases. 
 Scientists and Doctor’s concerns are that the stem cells they are being denied to use are autologous stem cells, 
these are cells extracted from the patient who seek treatment, these cells are expanded to reach therapeutic dose 
and re-infused to the same patient they were extracted from. The FDA’s responsibility is to regulate the proper 
use of drugs, of recent, the FDA has said that autologous stem cells should be regulated as drugs. This has 
coursed confusion for Scientists, Doctors and patients alike as to how can cells taken from an individual pose a 
medical concern when those cells are re-infused to the same individual. 
The FDA’s decision to regulate autologous stem cells has led to most Doctors moving their stem cell treatment 
centers to set up shop outside the USA. There are now hundreds of stem cell treatment centers (clinics) around 
the world providing treatment to a variety of diseases in countries where the regulatory laws against the use of 
autologous stem cells are not as strict as in the USA. 
The purpose of this book is to provide information or reference to both patients and Doctors about stem cells, 
and stem cell treatment centers around the world, such information includes countries where the centers are 
located, physical addresses, contact persons, treatment cost, sources of stem cells used in treatment, type of 
diseases/conditions being treated and the protocols or procedures used. This reference will work as a quick 
guide to recommended stem cell treatment centers that can address their relevant needs. Doctors will be able to 
refer their patients to a relevant treatment center and patients will know about the protocols used, source of stem 
cells and the treatment cost so that they can properly plan for their treatment. 
2. Stem Cell Expansion 
Adult stem cell (ASC) therapy  represent a promising treatment modality in regenerative medicine and tissue 
engineering. The challenge with ASC use in therapy is the fact that they are found in very small numbers. For 
them to reach therapeutic dose, the number of stem cells should not be less than 2x106 stem cells. In order to 
overcome this limitation, there is need to expand the number of ASC to manufacturing scale to benefit people 
and patients with different medical conditions. 
One way to achieve this is through culture methods, this has faced challenges because the culture media used 
has little potential of supporting their growth, hence the need to add growth factors, some of which include 
animal extracts like fetal bovine serum (FBS). The disadvantages with xenogenic serum is complicated because 
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of high lot-to-lot variability and is associated with a risk of transmitting infectious agents and immunizing 
effects. In some cases, immunological reactions and anti-FBS antibodies have been observed and considered as 
having possibly affected the therapeutic outcome.  
In order to overcome these challenges, there are promising studies that have demonstrated that for clinical scale 
manufacturing of ASCs, human factors from serum or platelets have been suggested as alternatives to FBS. In 
other studies, pooled human serum (HS) and thrombin-activated platelet releasate in plasma (tPRP) support the 
expansion of adipose tissue-derived Mesenchymal (MSCs) cells. In a study conducted by Karen Bieback et al 
2009, their results showed that MSC population doublings and expansion kinetics were significantly enhanced 
in pHPL-supplemented BM-MSC culture compared with cultures supplemented with selected FBS [6, 10]. 
Platelet-rich plasma (PRP) has gained importance in bone regeneration and healing since the α-granules of the 
platelets are rich in growth factors such as the vascular endothelial growth factors (VEGF), platelet-derived 
growth factor (PDGF) and transforming growth factor β (TGF-β) which play a key role in tissue healing [8]. 
In another study conducted by Melanie Vogl et al 2013, where the purpose of the study was to investigate 
whether tPR is able to increase the proliferation of MSCs especially MSCs of elderly donors. The supernatant of 
thrombin-activated platelet-rich plasma, the platelet releasate was found to be an excellent adjuvant in isolating 
and expanding human MSCs. The study also showed that tPR from pooled PRP influences significantly the 
proliferation of the MSC of young and mid-aged patients. The best proliferation rates were reached by adding 
5% tPR. MSCs from old patients, there was a trend in proliferation increase after the addition of Trp [11]. 
One of the breakthroughs in the use of autologous stem cell in therapy is the ability to expand them using 
autologous serum. A number of research studies including the one conducted by Akimoto Nimura et al 2010, 
which examined whether heat-inactivation of serum affected the proliferation and whether autologous human 
serum influenced their multipotentiality made the use of human serum recommended for clinical use. Akimoto 
indicated that increasing the safety of medical treatments with MSCs requires the use of autologous human 
serum, in his study, he discovered that autologous human serum significantly increased the proliferation of 
synovial MSCs in contrast, compared with fetal bovine serum [1].  
Autologous serum/plasma has successfully been used as a stem cell expansion supplement for in vitro culture of 
CD34+ cord blood, and proliferation of hematopoietic progenitor cells was markedly increased with serum 
supplements taken 4 or 8 days before HSCs implantation. To prove the significance of autologous/pooled 
human plasma, analysis of platelet releasates, lysates and sub-cellular fractions has shown that numerous 
bioactive molecules are stored within distinct platelet organelles including adhesive proteins, coagulation 
factors, mitogens, protease inhibitors and proteoglycans. Compared with serum, Buffy coat-derived platelet 
preparations are of particular interest because they do not complete with Red Blood Cells and plasma 
preparation for the limited available blood donations [3]. 
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2.1 Automated Stem Cell Expansion 
The large number of ex vivo expanded cells that are required in many clinical cell protocols greater than  two 
million cells (2x106)  per patient makes standard culture conditions problematic and expensive, resulting in need 
for extensive personnel and facilities resources and the potential for contamination. To meet such clinical 
demand, a robust automated and closed cell expansion method is optimal.  
Specific steps taken to multiply the number of stem cells for re-implantation include; isolation of the stem cells 
from the patient’s blood sample, by manual procedures or automated, e.g.; by using the Res-Q 60 BMC System 
(from CESCA Therapeutics). After isolation, the stem cells are counted (using hemocytometer etc) to determine 
cell density and viability, the cells can now be expanded by use of specific culture media (StemPro-34, 
StemSpan H2000 for HSCs). At this stage, the patient’s serum/plasma can be incorporated into the expansion 
culture media as supplement to provide required nutrients. The cultures are incubated at 37°C for 7-14 days. 
After incubation, the cultures are removed and the cells are counted and prepared for implantation. An expected 
number of HSCs at the end of the expansion process is two million cells a number required to achieve a 
therapeutic dose [7].  
3. Sources of Stem Cells 
For many years, researchers have been seeking to understand the body’s ability to repair and replace the cells 
and tissues of some organs, but not others. After years of work pursuing the how and why of seemingly 
indiscriminant cell repair mechanisms, scientists have now focused their attention on adult stem cells. It has 
long been known that stem cells capable of renewing themselves and that they can generate multiple cell types.  
Today, there is new evidence that stem cells are present in far more tissues and organs than once thought and 
that these cells are capable of developing into more kinds of cells than previously imagined. Efforts are now 
underway to harness stem cells and to take advantage of this new found capability, with the goal of devising 
new and more effective treatments for a host of diseases and disabilities. What lies ahead for the use of adult 
stem cells is unknown, but it is certain that there are many research questions to be answered and that these 
answers hold great promise for the future.  
Like all stem cells, adult stem cells share two characteristics, they can make identical copies of themselves for 
long period of time, this ability is called long-term self-renewal. Adult stem cells can also give rise to mature 
cell types that have characteristic morphologies and specialized functions. ASCs are dispersed in tissues 
throughout the mature animal and behave very differently, depending on their local environment, for example, 
hematopoietic stem cells (HSCs) are constantly being generated in the bone marrow where they differentiate 
into mature types of blood cells [5]. 
Unlike embryonic stem cells which are defined by their origin (inner cell mass of the blastocyst), ASCs share no 
such definitive means of characterization. No one knows the origin of ASCs in any mature tissue. Definitions of 
ASCs vary in the scientific literature range from a single description of the cells to a rigorous set of 
experimental criteria that must be met before characterizing particular cell as an adult stem cell. The list of adult 
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tissues reported to contain stem cells includes bone marrow, peripheral blood, brain, spinal cord, dental pulp, 
blood vessels, skeletal muscle, epithelia of the skin and digestive system, cornea, retina and pancreas. 
ASCs should be clonogenic, a single ASC should be able to generate a line of genetically identical cells, which 
then give rise to all the appropriate differentiated cell types of which it resides. An ASC should also be able to 
give rise to fully differentiated cells that have mature phenotypes, are fully integrated into the tissue. Phenotype 
refers to all the observable characteristics of a cell, interactions with other cells and the non-cellular 
environment, proteins that appear on the cell surface and the cell behavior. 
In order to fully characterize the regenerating and self-renewal capabilities of the ASC, and therefore truly 
harness its potential, it will be important to demonstrate that a single ASC can generate a line of genetically 
identical cell types of the tissue in which it resides. 
If ASCs are to be prepared for therapeutic application, there should be evidence that there are ASCs present in 
the cell preparation. There are three methods used to determine whether candidate ASCs give rise to specialized 
cells. ASCs can be labeled in vivo and then they can be tracked. Candidate ASCs can also be isolated and 
labeled and then transplanted back into the organism to determine what becomes of them. Finally, candidate 
adult stem cells can be isolated, grown in vitro and manipulated, by adding growth factors or introducing genes 
that help determine what differentiated cells types they will yield. For an example, currently, Scientists believe 
that stem cells in the fetal and adult brain divide and give rise to nerve cells, of which there are many types [8, 
9]. 
It is often difficult to distinguish adult tissue-specific stem cells from progenitor cells, which are found in fetal 
or adult tissues and are partly differentiated cells that divide and give rise to differentiated cells. These are cells 
found in many organs that are generally thought to be present to replace cells and maintain the integrity of the 
tissue.  
To be able to claim that ASCs demonstrate plasticity, it is first important to show that a cell population exists in 
the starting tissue that has the identifying features of stem cells. Then it is necessary to show that the ASCs give 
rise to cell types that normally occur in a different tissue. Proving the existence of an ASC population in a 
differentiated tissue is a laborious process. It requires that the candidate stem cells are shown to be self-
renewing, and that they can give rise to the differentiated cell types that are characteristic of the tissue. 
To show that ASCs can generate other cell types requires them to be tracked in their new environment, whether 
be it in vitro or in vivo. In general, this has been accomplished by obtaining the stem cells from a mouse that has 
been genetically engineered to express a molecular tag in all its cells.  It is then necessary to show that the 
labeled ASCs have adopted key structural and biochemical characteristics of the new tissue they claim to have 
generated. It is necessary to demonstrate that the cells can integrate into their new tissue environment, survive in 
the tissue and function like the mature cells of the tissue.  
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3.1 Cord Blood 
Cord blood is a sample of blood taken from a newborn baby's umbilical cord. It contains a rich source of stem 
cells, which could potentially be used in the treatment over 75 different diseases, including leukemia, lymphoma 
and anemia. Many expecting parents choose to bank their newborn's cord blood, as it may be useful in the 
future, should the child or a related family member fall victim to a disease that is potentially treatable by cord 
blood stem cells. Cord blood is obtained by syringing out the placenta through the umbilical cord at the time of 
childbirth, after the cord has been detached from the newborn. Cord blood is collected because it contains stem 
cells including hematopoietic cells, which can be used to treat hematopoietic and genetic disorders. One unit of 
cord blood generally lacks stem cells in a quantity sufficient to treat an adult patient [13, 16]. 
The original clinically attractive feature of cord blood was the high concentration of hematopoietic stem cells, 
which is similar to that found in bone marrow 0.1-0.8 CD34+ cells per 100 nucleated cells. In addition to being 
a source of hematopoietic cells, cord blood contains potent angiogenesis stimulating cells. The CD34+, CD11b+ 
fraction, which is approximately less than half of the CD34+ fraction of cord blood which was demonstrated to 
possess ability to differentiate into functional endothelial cells in vitro and in vivo.  
In addition to endothelial progenitors, mesenchymal stem cells found in cord blood are known to secrete 
numerous cytokines and growth factors such as VEGF and FGF-2 which stimulate angiogenic processes. 
Mesenchymal stem cells are capable of differentiating into various non-hematopoietic tissues. Mesenchymal 
stem cells are classically defined as capable of adhering to plastic and expressing a non-hematopoietic cell 
surface phenotype consiting of CD34-, CD45-, HLA-DR-, while possessing markers such as STRO-1, VCAM, 
CD13, CD29, CD44, CD90, CD105, SH-3. Mesenchymal stem cells have been purified from bone marrow, 
adipose tissue, placenta, scalp tissue and cord blood-derived mesenchymal stem cells have demonstrated the 
ability to differentiate into a wide variety of tissues in vitro including neuronal, hepatic, osteoblastic and cardiac 
[5]. 
An important aspect of this cell population is their anti-inflammatory and immunomodulator activity. For 
example, they constitutively secrete immune inhibitory cytokines such as IL-10 and TGF-β while maintaining 
ability to present antigens to T cells, thus suggesting they may act as a tolerogenic antigen presenting cell. Cells 
with markers and activities resembling embryonic stem cells have been found in cord blood. A population of 
CD34- cells expressing OCT-4, Nanog, SSEA-3 and SSEA-4, which could differentiate into cells of the 
mesoderm, ectoderm and endoderm lineage have been identified. 
In the 1930s, it was reported that cord blood could be safely used as a substitute for peripheral blood for 
performing transfusions. Since HLA-matching was not available at that time and no adverse effects were noted. 
A resent lancet publication described the use of cord blood as a source of blood donation for malaria infested 
regions in Africa where 85 ml of ABO matched cord blood with no HLA matching. No report of graft versus 
host was noted [19, 28]. 
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3.2 Bone marrow and Peripheral Blood 
The constant and continued supply of blood and its components to body tissues and organs is dependent on the 
constant and continued production and replenishing of the same. We know that all blood cells have a life span, 
for example, red blood, have a life span of 120 days, after which they are destroyed as they pass through the 
spleen. This means that these cells should be replaced by new ones. The system that does that is called the 
Hematopoietic System.  
An average human requires approximately one hundred billion new hematopoietic cells each day. The continued 
production of these cells depends directly on the presence of the Hematopoietic Stem Cells (HSCs), ultimate and 
the only source of these cells. For decades, treatment for hematopoietic disorders has been by bone marrow 
transplant, however, this has encountered various limitations including the issue of Graft versus Host disease 
and the transmission of viruses like Cytomegalo Virus (CMV) and in-availability of donors etc.  
Apart from being used to correct hematopoietic disorders, bone marrow is also used for cartilage repair because 
of its abundance in stromal cells also known as Mesenchymal stem cells which play a major role in cartilage 
repair, amongst its many functions. Since the procedure for obtaining a bone marrow sample is labor intensive 
as it requires recipient and donor tissue matching, and it is a very invasive procedure because the donor is put 
under anesthesia and a big needle is drilled to the hipbone or sternum to get a sample. Scientists have looked 
into possibilities of avoiding the painful procedure by demonstrating the presence of MSCs in peripheral blood, 
which can then be used as the procedure for harvesting whole blood (peripheral) is easy, less painful and quick 
compared to bone marrow harvesting procedures. bone marrow being the only tissue containing MSCs. 
Roufosse et al mentions that during tissue damage, MSCs are transported from the bone marrow to the damaged 
site via circulating peripheral blood to promote regeneration . This means that it is possible to get MSCs in 
peripheral blood. Using the procedure known as Blood mobilization using Granulocyte colony stimulating 
factor (G-CSF) increases the number of MSCs in peripheral blood. It has also been demonstrated that this 
technique does not selectively produce MSCs but rather a mix of MSCs. Bone marrow stromal cells generate 
cartilage, bone, and fat. Yuji Takahara et al carried experiments that proved the restorative effects of Adipose-
derived mesenchymal Stem Cells on damaged ovarian function, this proves that MSCs can also be derived from 
Adipose tissue, not only in the bone marrow [1, 3, 16]. 
CD34 is a cluster of differentiation molecule present on certain cells within the human body. It is a cell surface 
glycoprotein and functions as a cell-cell adhesion factor. It may also mediate the attachment of stem cells to 
bone marrow extracellular matrix or directly to stromal cells. The concern about cells expressing CD34+ marker 
would mean contamination of the MSC culture with other cells like fibroblast which express the molecule 
CD34+.  
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3.3 Placenta and Amniotic fluid 
Recent studies show that amniotic fluid contains a considerable quantity of stem cells. These amniotic stem cells 
are pluripotent and able to differentiate into various tissues, which may be useful for future human application. 
Some researchers, including Anthony Atala of Wake Forest University, a team from Harvard University, and 
Italian Paolo de Coppi, have found that amniotic fluid is also a plentiful source of non-embryonic stem cells. 
These cells have demonstrated the ability to differentiate into a number of different cell-types, including brain, 
liver and bone. The placenta is a much better source of stem cells since it contains up to ten times more than 
cord blood. Some placental blood may be returned to the neonatal circulation if the umbilical cord is not 
prematurely clamped [1, 16]. 
3.4 Adipose Tissue 
Adult stem cells (ASCs), originally identified as a source of osteoprogenitor cells, MSCs differentiate into 
adipocytes, chondrocytes, osteoblasts and myoblasts in vitro and undergo differentiation in vivo making these 
stem cells promising candidates for mesodermal defect repair and disease management. However, the clinical 
use of MSCs has presented problems, including pain, morbidity and low cell number upon havest. This has led 
to researchers to investigate alternate sources for MSCs. 
Adipose tissue, like bone marrow, is derived from the mesenchyme and contains a supportive stroma that is 
easily isolated. Based on this, adipose tissue may represent a source of stem cells that could have far-reaching 
effects on several fields. Compared to any other source, the high concentrations of generative cells found in 
adipose tissue, especially in the abdominal region, by sheer volume of availability, ensure an abundance in the 
number of ASCs ranging in the millions per unit volume. The sheer number available also has the added 
advantage of not needing to be cultured in a laboratory over days in order to get the desired number of ASCs to 
achieve therapeutic threshold. 
Adipose tissue ASCs (AT-ASCs) are extremely similar to stem cells isolated from bone marrow (BMASCs). 
The similarities in profile between the types of ASCs range from morphology to growth to transcriptional and 
cell surface phenotypes. Their similarity extends also to their developmental behavior both in vitro and in vivo. 
This has led to suggestions that adipose-derived stem cells are in fact a mesenchymal stem cell fraction present 
within adipose tissue. Clinically, however, stromal vascular fraction-derived AT-ASCs have the advantage over 
their bone marrow-derived counterparts, because of their abundance in numbers, eliminating the need for 
culturing over days to obtain a therapeutically viable number and the ease of the harvest procedure being less 
painful than harvest of bone marrow [4, 16]. 
This in theory means that an autologous transplant of adipose-derived ASCs will not only work in much the 
same way as the successes shown using marrow-derived mesenchymal stem cell transplant, but also be of 
minimal risk to the patient. AT-ASCs, like BM-ASCs, are called mesenchymal ASCs because they are both of 
mesodermal germ origion. This means that AT-ASCs are able to differentiate into specialized cells of 
mesodermal origin such as adipocytes, fibrocytes, fibroblasts, myocytes, osteocytes and chondrocytes. 
171 
 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2015) Volume 22, No  2, pp 161-190 
4. Clinical Trials 
Clinical trials are sets in medical research and drug development that generate safety and efficacy data or more 
specifically, information about adverse drug reactions and adverse effects of other treatments for health 
interventions. They are conducted only after satisfactory information has been gathered on the quality of the non 
clinical safety and health authority/ethics committee approval is granted in the country where approval of the 
drug or device is sought. 
Investigators initially enroll volunteers and /or patients into small studies and subsequently conduct larger scale 
studies in patients that often compare the new product with others already approved for the affliction of interest. 
Clinical trials often involve patients with specific health conditions who then benefit from receiving otherwise 
unavailable treatments. 
 
Figure 3: Separation of Adult Stem Cells from Adipose Tissue. 
 
A discussion from the Drake Institute in regards to ‘clinical trials’ states that clinical trials have no place in stem 
cell studies because each patient can serve as his/her own control. With all the modern technology for objective 
assessment of a patient’s medical condition, there is no need for a randomized study. Each patient can be 
carefully evaluated before and after treatment, by objective medical testing using various equipment and their 
condition after therapy compared to that before. Clinical trial format is not relevant nor applicable to patient 
specific therapy involving adult stem cells or even adult fetal stem cells [12]. 
This type of experimentation is certainly appropriate for animals but not humans, stem cell therapy does not 
involve any drug. Particularly with respect to the injection of autologous stem cells, that are found naturally in 
the patient, the patient is receiving what one already has, just more of it, in a clinical trial half the patients are 
chosen at random to receive a placebo, while half of the patients are given an experimental drug, clinical trials 
are not necessary for stem cell treatments because stem cells are not drugs. 
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Many studies that have been conducted are proof enough that clinical trials for stem cells are not required, in 
particular, a study carried out by Suphachai Chaithiraphan et al  in Thailand where blood-born  angiogenic cell 
precursors (ACPs) harvested from patient’s peripheral blood, cultured and expanded and later injected 
intracoronary in patients who were considered in advanced-stage ischemic heart disease [15]. 
Informed consent was obtained from all patients before the procedure. This clinical study was a non-randomized 
open study of consecutive patients with chronic coronary artery disease. Clinical trials are not necessary for 
stem cell treatments because the cells used in most cases are autologous stem cells. Autologous transplant is a 
type of transplant that uses the patient’s own stem cells. These cells are collected in advance and returned to the 
patient at a later stage. They are used to replace stem cells that have been damaged by high doses of 
chemotherapy or to treat the patient’s underlying disease. 
Autologous transplants are used to treat a number of different blood cancers, leukaemias lymphomas, myeloma, 
certain solid tumors, breast cancer, testicular cancer osteosarcoma and a lot more diseases. 
Stem cells used in autologous transplant are adult stem cells, these are cells that can make identical copies of 
themselves for long periods of time, this ability to proliferate is referred to as long-term self-renewal. Adult stem 
cells can give rise to mature cell types that have characteristic morphologies and specialized functions. 
Their primary function is to maintain a steady state functioning of a cell called homeostasis and with limitations, 
to replace cells that die because of injury or disease. Adult stem cells are dispersed in tissues throughout the 
mature animal and behave very differently depending on their local environment.  
5. Patient specific Trials 
There are stem cells in every body’s body that can be used to treat or manage an individual’s medical condition. 
In many situations they only have to be harvested, isolated, slightly improved or grown to larger numbers and 
then placed back in the right spot in the right way. Since these are not mass-produced drugs, but your own body 
tissues, applying a mass-manufacture regulatory regime to your cells makes no common sense, yet that’s what 
the FDA, big pharma and major universities want. Since your Doctor using your stem cells as body tissues 
instead of drugs spells financial ruin to them. 
Stem cells are cells that are capable of turning into other types of cells to help repair damaged tissue, they are all 
over our bodies, in almost every tissue. The commonly used stem cells in therapy are adult stem cells (ASCs) 
which have no negative stigma that pervaded embryonic stem cell research. Stem cell therapy is typically 
autologous, meaning the cells are taken from one’s own body and then re-injected back into a specific area to be 
treated. No embryos are harmed, and the cells come directly from the person being treated.  Autologous ASCs 
have emerged as a viable form of treatment for a number of diseases and conditions. 
Since in traditional clinical trials, not all the participants receive the drug under study, the FDA does give 
approval to institutions involved in the approval of scientific study protocols involving human subjects, these 
could include Science and Ethics Committees, Hospitals, manufacturing companies and Institutional Review 
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Boards (IRB). This has made it possible patient specific clinical trials, also called ‘’patient sponsored’’ studies. 
Such studies with autologous stem cells do not require government sponsorship, the patient pays for the study, 
there is no randomized or double blind study, every patient receives the treatment and both doctor and the 
patient know they are receiving the treatment and what the treatment is. 
There are several patient sponsored autologous stem cell treatment studies in the USA that meets the current 
FDA guidance and requirements. One study conducted by a US based company called Bioheart has conducted a 
patient specific stem cell treatment for Diabetes type II, in conjunction with Repair Stem Cell Institute starting 
in April 2014.  
 
5.1 The Food and Drug Administration’s (FDA) view on Clinical use of Stem Cell  
Stem cell treatment centers in the USA have been faced with challenges in regards to access to stem cell therapy 
for every one due to FDA regulatory laws which have been made to regard autologous stem cells as drugs. This 
translates to saying that if your cells are drugs, you no longer control them and their use, instead, their use would 
be governed by federal drug laws rather than your needs. Under current regulatory, policy, even if the cells in 
your body could be used by your Doctor to save your life one day, you legally do not have the right to use them 
for that purpose if FDA requirements are not met. 
The FDA has always claimed that there isn’t enough research and clinical trials to substantiate the use of stem 
cells in therapy. The truth of the matter is that there is currently over 167, 879 published studies on stem cells 
listed in the USA national library of medicine. Just on mesenchymal stem cells alone there is17,632 studies 
available. For comparison purposes, there are only 13,118 papers investigating the use of the most commonly 
used antibiotic, amoxicillin, for which 52.3 million prescriptions were written in 2010. The newly approved 
immunology drug, belimumab, there are only 140 research papers listed, in terms of the volume of published 
knowledge, there is approximately 12,500 more known about a single adult stem cell type than this newly 
approved drug.  
By 2009, there had already been more than15,000 cord blood transplants worldwide. In the USA, more than 
one-half of all stem cell transplants from unrelated donors in children now use cord blood. Most pediatric 
patients who have received cord blood transplants were affected by leukemia, lymphoma, servere aplastic 
anaemia, and other lethal diseases of the blood or immune system as well as certain inherited metabolic 
diseases. Despite the fact that cord blood banks have been saving lives with this tissue, for more than a decade, 
the FDA announced in 2009 that cord blood should be treated as a drug. As a result, the costs to obtain cord 
blood have markedly increased while the safety profile remains unchanged.  
Adipose cells are processed at the bed side during fat-transfer surgeries where a surgeon moves fat from one 
part of the body and places it in another. The basic procedure has been performed for more than a century. 
However, the FDA has asserted that if the structure of the fat is broken down, as is common in a new same day 
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stem cell procedure being performed by physicians, then this creates a drug of the patient’s own cells. The 
FDA’s Tissue Reference Group (TRG) has sent letters to physicians performing adipose cell transfers, stating 
that even if they process these cells during the same surgical procedure in their offices with no culture involved, 
the practice is still creating a new drug. 
The FDA has much less stringent regulations if, for example, a company wants to sell cadaver bone for use in 
surgery in that these products aren’t treated the same as a new drug, the only requirement is that you follow a 
minimal set of safety standards processing the tissue and you test for communicable diseases. 
A company called Cytori Therapeautics, created a new device to process fat to isolate stem cells resident in the 
tissue, this is a simple process, and in Europe, the machine was quickly granted approval. In the USA, however, 
the part of the FDA that regulates stem cells has made it a nightmare to get the machine approved. While the 
FDA admitted the machine does what it says it should do and produces a mix of cells free from contamination, it 
claimed that since the product of the machine was the patient’s own stem cell mix, it would consider the 
machine the same as a new drug. The big concern raised was that the machine’s stem cell mix could be used off-
label by a Doctor [4, 11].  
6. Current USA Stem Cells Treatment 
The United States Food and Drug Administration (FDA) claims that a patient’s own stem cells are a drug which 
it intends to regulate. This means that clinical trials are required and a physician must submit his treatment for 
approval. Since it was enacted in 1938, the Food, Drug, and Cosmetic Act (FDCA) has regulated medical drugs 
and devices based on basic public health concepts that recognize the differences between the practice of 
medicine and mass production of drugs. The regulation of mass manufactured and widely distributed medical 
products led to a revolution in healthcare that greatly increased public safety and unquestionably saved lives due 
to the reduction of unsafe products. 
Things changed in 2006, when the FDA, without public commentary, altered a single word in its regulatory 
language regarding cell and tissue based therapies that moved their focus from protecting the public from 
communicable disease transmission to asserting authority over virtually all therapies using autologous cells and 
tissue. Most organizations have noted that the FDA was only granted authority by the U.S Congress to regulate 
allogeneic tissue transplants in order to control communicable disease transmission and that the Agency had no 
authority to regulate human cells of any type like mass produced prescription drugs. Other organizations have 
indicated that stem cell transplants are medical procedures, their use is the practice of medicine, not the 
manufacturing of a drug as the FDA asserts. 
In 2008, the FDA sent a notice to Regenerative Sciences, a medical practice that utilized expanded bone marrow 
derived mesenchymal stem cells for autologous orthopedic use. The FDA asserted that their drug mass 
production rules applied to the practices at the clinic. The Agency has recently made a worrisome assertion 
about the processing of adipose tissue, a medical practice that has been around for more than 100 years. The 
claim is that, any isolation of the stem cell rich fraction of fatty tissue for orthopedic use by physician for his or 
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her own use in patients equates to the manufacture of a drug, even if that tissue is processed at the bedside. 
Congress had only authorized the FDA classify a substance that affected the body through ‘’chemical action’’ as 
a drug, the Agency needed to clarify its position as to why a patient’s own stem cells could be considered a 
drug. The Agency responded by saying that ‘’when living cells interact with their environment to mediate repair 
and/or generate damaged tissue, they do so by chemical action.’’ The Regenexx procedures are a family of non-
surgical stem cell and blood platelet treatments for common injuries and degenerative joint conditions, such as 
osteoarthritis and avascular necrosis. These stem cell procedures utilize a patient’s own stem cells or blood 
platelets to help heal damaged tissues, tendons, ligaments, cartilage, spinal disc or bone. It works by taking a 
blood sample and a bone marrow sample from a patient and separating out stem cells via centrifuge, then re-
infuse those cells directly into the injured area where they assimulate into the bone or cartilage and begin to 
regenerate it [11] 
Regulators have argued that the Regenexx procedure is equivalent to the administration of a drug because the 
stem cells that are re-injected into patients constitute an article that is intended to treat, cure and mitigate 
diseases and to affect the structure and function of the patient’s body, therefore fitting within the definition of 
‘drug’. 
7. International Stem centers by country 
Special thanks goes to all the treatment centers that were kind enough to share information about their treatment 
centers, this information is meant to assist both physicians and patients who seek stem cell treatment to quickly 
identify treatment centers that may be suitable for their needs because not all stem cell treatment centers can 
treat all conditions. 
Most of the stem cell treatment centers listed in this chapter are those that were contacted through email and 
other means, it is worth mentioning that some centers are also included because most of the required 
information to guide a patient or physician is available in the center’s web page and some centers, especially 
those that have treatment centers in multiple countries, failed to share the information required for this reference 
because they felt that instead of reaching the centers through the contact or spoke’s person for the treatment 
centers, they tend to visit the stem cell treatment centers direct, this may not be good business for those using 
the centers as income generation source. Since this is a first edition of such a compilation of International Stem 
Cell Treatment centers, it is hoped that more information on centers that failed to respond before this publication 
will be included in the second edition of this reference. It is worth mentioning that this reference does not 
include accreditation/good standing of these centers with regulatory bodies within their countries. 
1. United States of America (USA) 
A. Name of treatment center:  Stem Cell Rejuvenation Center 
Website  
http://www.center.com/FAQ.html 
Physical Address 
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7600 N. 15th Street Ste. 102 
Phoenix, AZ 85020 
Telephone  
(602)439-0000 office 
(602)439-0021 fax 
Contact Person 
Josh 
Email 
info@the-stem-cell-center.com 
Diseases/conditions Treated 
1. ALS 
2. Alzheimer’s 
3. Autism  
4. Cerebral Palsy 
5. Degenerative Disc Disease 
6. Erectile dysfunction 
7. Glaucoma 
8. Hearing loss 
9. Heart disease 
10. Huntington Disease 
11. Kidney failure 
12. Liver Disease 
13. Macular Degeneration 
14. Muscular Dystrophy  
15. Optic nerve injury 
16. Parkinson’s Disease 
17. Pulmonary Fibrosis 
18. Renitinitis Pigmentosa 
19. Spinal cord injury 
20. Stroke 
21. Diabeties  
22. Lupus  
23. Multiple scleroses 
24. Rhematoid arthritis 
Source/Type of stem cells used 
Autologous Adipose Stem Cells 
Procedure/Protocol used  
A small sample of adipose tissue is removed from above the superior iliac spine or abdomen under local 
anesthetic. Adipose tissue contains much larger volumes of mesenchymal stem cells than does bone marrow 
extraction.  
177 
 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2015) Volume 22, No  2, pp 161-190 
Estimated Costs 
Stem Cell consultation and treatment: $7,600.00 
 
B. Name of treatment center: Regenexx Stem Cell Treatment Center/Centeno-Schultz Clinic 
Website 
www.regenexx.com 
Physical Address 
403 Summit Blvd.,  Suite 201 
Broomfield, CO 80021 
Telephone 
303-495-4014 
Toll Free: 1-888-525-3005 
Contact Person/Patient Liaison 
Che DeMarco 
Diseases Treated 
1. Degenerative joint conditions 
2. Common injuries 
3. Osteoarthritis 
4. Vascular necrosis 
5. Arthritis 
Source of Stem Cells 
Autologous Blood sample and bone marrow 
Treatment Costs 
Range from $4000 - $8000 
Procedure/Protocol 
Regenexx works by taking a blood sample and a bone marrow sample from a patient and separating out the stem 
cells via centrifugation, then re-injecting those cells directly into the injured area, where they assimilate into the 
bone or cartilage and begin to regenerate it. 
 
C. Name of treatment center: Miami Stem Cell Treatment Center 
Website 
http://www.miamistemcellsusa.com 
Physical Address 
Boca Raton 
Miami Stem Cell Treatment Center 
1515 North Federal Highway 
Suite 105 
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Boca Raton, Florida, 33432 
Telephone 
(561) 331-2999 
Fax 
(561) 331-2998 
(Miami Stem Cell Treatment Center comprises of 4 others centers, reachable at the same phone numbers) 
Contact Person (s) 
Nicole Rintrona 
Dr. Thomas A. Gionis 
Dr. Nia Smyrniotis 
Email  
Dr.Gionis@MiamistemCellsUsa.com 
Dr.Nia@MiamiStemCellsUsa.com 
Diseases/Medical conditions Treated 
1. Cardiac –Pulmonary 
2. Neurologic 
3. Orthopedic 
4. Spine 
5. Autoimmune Diseases 
Sources of Stem Cells 
Adult Autologous Aipose-derived Stem Cells (ADSCs) 
Cost 
$8,900 
Procedure/Protocol 
The stem cells come from stromal vascular fraction (SVF), a protein rich segment from processed adipose 
tissue. Stromal vascular fraction contains a mononuclear cell line predominantly with mesenchymal stem cells, 
macrophages, endothelial cells, and growth factors that facilitate the stem cell processes and promote their 
activity. The SVF is harvested, concentrated, then deployed back into the patient’s body via injection or 
intravenous infusion on an outpatient bases. 
 
D. Name of treatment center:  Northwest University, Feinberg School of Medicine. Division of 
Immunotherapy and Autoimmune Diseases (DIAD) 
Website  
Http://www.stemcell-immunotherapy.com 
Physical Address 
Division of Immunotherapy and Autoimmune Diseases 
Northwest University, Feinberg School of Medicine 
446 E Ontario ste 10-1000 
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Chicago, IL 60611 
Contact Person 
Ms. Kate Quigley 
Telephone 
312-695-4960 
312-695-4961 (fax) 
Email 
info@stemcell-immunotherapy.com 
Diseases/Conditions Treated 
1. Autoimmune Bullous skin disorders 
2. Retinopathy and Optic Neuropathy 
3. Chronic Inflammatory Demyelinating Polynaropathy 
4. Crohn’s Devic’s Disease 
5. Idiopathic Inflammatory Myopathy Disease 
6. Leukocyte Adhesion Deficiency Type 1 
7. Multiple Sclerosis 
8. Myasthenia Gravis 
9. Primary Biliary Cirrhosis 
10. Pulmonary Fibrosis 
11. Rheumatoid Arthritis 
12. Sarcaidosis 
13. Scleroderma 
14. Systemic Lupus Erythematosus 
15. Systemic Necrotizing Vasculitis 
16. Morphea 
17. Type 1 Diabetes 
Sources of Stem Cells used 
1. Peripheral Blood 
2. Umbilical Cord Blood 
Treatment Cost 
Not provided 
Procedure/Protocol 
Treatment protocol includes four phases: 
Phase I: Pre-transplant Testing include MRI, CT, scans, Blood work, Pulmonary function tests. This is followed 
by admission to the hospital overnight for chemotherapy, then discharged the following day after fluid 
hydration. 
Phase II: After being discharged, the patient gives himself/herself the shorts to grow stem cells (neupogen) 
Phase III: Stem cells are collected by apheresis. 
Phase IV: The patient is admitted to the hospital for transplant. The patient receives IV fluids followed by 
chemotherapy and receiving his/her stem cells (similar to blood transfusion)  
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2. Argentina 
A. Name of treatment center: Fernandez Vina Foundation 
Physical Address 
The legal Address for this center is that of the Contact Person; 
Don Margolis 
Repair Stem Cell Institute 
3010 LBj Freeway, Suit 1200 
Dallas, TX75234 
Telephone 
(214) 556-6377 
Email 
donmargolis@gmail.com 
Diseases/Conditions Treated 
1. Heart Disease 
2. Lung Disease 
3. Diabetes 
Source of stem cells 
Bone marrow autologous stem cells 
Treatment Costs 
$14,900 
 
3. Panama 
A. Name of treatment center: Panama Stem Cell Institute 
 
Website 
Http://www.cellmedicine.com 
Physical Address 
Plaza Pacific Office #2A 
Via Israel Calle 66y 67 
Via Israel, Ciadad de Panama 
Panama 
Contact person 
Dr. Neil H. Riordan 
Diseases/Conditions 
1. Autism 
2. Cerebral Palsy 
3. Heart Failure 
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4. Multiple Sclerosis 
5. Osteoarthritis 
6. Rheumatoid Arthritis 
7. Spinal Cord Injury 
8. Autoimmune Diseases 
Source of Stem Cells 
1. Bone marrow 
2. Adipose Tissue 
3. Cord Blood 
Treatment Cost 
Not provided 
Procedure/Protocol 
Type of stem cells used and protocol used may depend upon individual condition. What is interesting will the 
protocols for the conditions treated by this center is that Umbilical Cord Blood is used in all the protocols. 
For Autism, CP, and Heart disease, the source of stem cells used is allogeneic Umbilical Cord Blood. This cord  
blood come from donated umbilical cords. Because HLA matching is not necessary, anyone can be treated with 
allogeneic cord blood. Allogeneic stem cells can be administered multiple times over the course of days in 
uniform dosages that contain high level counts. Umbilical cord tissue provides an abundant supply of 
mesenchymal stem cell. Protocols include three phases,  4 infusion of allogeneic mesenchymal stem cells, 2 
infusion of allogeneic mesenchymal stem cells and two, 2 infusion of mesenchymal stem cells followed by 1 
infusion at two intervals. For MS, Osteoarthritis, Rheumatoid Arthritis and Autoimmune disease, the stem cells 
used are Fat tissue and Umbilical Cord and the procedure of administering is the same. For treating spinal cord 
injury, the stem cell source is the bone marrow and cord blood. 
 
4. India 
A. Name of treatment center: Chaitanya Stem Cell Center 
Website 
Http://www.chaitanyastemcell.com 
Physical Address 
Rahi Sakha Apt S.No. 133 
Pune-Sinhagad Road, Parrati 
Pune 411030 
Contact Person 
Anant Bagul 
Email 
anantbagul@yahoo.com 
Telephone 
020-243329666 
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+91 9011-111-222 (mobile) 
Diseases/conditions Treated 
1. Autoimmune 
2. Eye conditions 
3. Paediatric neurological disorders 
4. Metabolic diseases 
5. Chronic Kidney disease 
6. Antiaging 
7. Chacort Mariet tooth 
8. Liver 
9. Polio 
Source of Stem Cell 
Fetal Stem Cell 
Treatment Cost 
Not provided 
5. Israel 
A. Name of Treatment Center: International Center for Cell Therapy and Cancer Immunology 
Website 
http://www.ctcicenter.com 
Physical Address 
Weizmann Center 
20th floor – Top Ichilov 
14 Weizmann Street 
Tel Aviv 64239 
Israel 
Contact Person 
Ruth Grunbaum 
Email 
info@ctcicenter.com 
Telephone 
Phone +972 77 777 9255 
Fax +972 77 777 9247  
Diseases/Conditions Treated 
1. Hodgin’s Disease 
2. Myelodysplastic syndromes 
3. Multiple Myeloma 
4. Hematological solid tumors 
5. Chemoresistant metastatic solid tumors 
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6. Multiple Sclerosis 
7. Aplastic Anamia 
8. Fanconi’s anemia 
9. SCID 
10. Spinal cord injury 
11. Parkinson’s 
12. Stroke 
13. Autism 
14. SLE 
15. Crohn’s disease 
16. Beta Thalassemia 
17. Sickle cell anemia 
18. Gaucher’s disease 
19. Hurler’s disease 
20. Metachromatic leukodystrophy etc. 
Source of Stem cells used 
1. Autologous mesenchymal stem cells isolated from bone marrow or adipose tissue  
Treatment Cost 
Not provided 
Procedure/Protocol 
Transplants may be autologous or from cells cryopreserved cord blood or allogeneic cells 
The bone marrow transplant procedure is used to restore a patient’s immune system after intence chemotherapy 
directed at a serious cancer like leukemia has destroyed the patient’s immune system. It is directed at re-
establishing an effective immune system by using a donor’s healthy immune cells to augment the patient’s own 
immune system without the donor cells being rejected, to strengthen the patient’s own cancer defense response. 
A fully myeloablative bone marrow transplantation procedure is performed in a hospital under clean and 
isolated conditions since the patient ‘s own immune system is destroyed by the process, and the patient has no 
natural defenses during the period it takes for the transplanted stem cells to create new functioning white blood 
cells. CTCI also provides several types of dendritic cell therapeutic vaccines which patients take after they 
already have cancer. These therapeutic vaccines are made from two main ingredients, dendritic cells plus 
antigens (biomarkers) of the cancer being treated. The biomarkers are obtained from the patient’s own tumor 
tissue, if not, they are obtained from a bank or library. Dendritic vaccines are designed to activate dendritic 
cells, so that they can accomplish the mobilization of the whole immune system. 
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6.  Thailand  
A. Name of Treatment center: Stem Cells Thailand 
Website 
http://stemcellthailand.org 
Contact Person 
Not provided 
Diseases/Conditions treated 
1. Heart diseases 
2. Kidney disease 
3. Autism Spectrum 
4. Brain injuries 
5. Cerebral Palsy 
6. Fibromyanlgia 
7. Cartilage and ligament 
8. Alzheimers 
9. Rett syndrome 
10. Spinocerebral ataxia 
And many more 
 
Sources of Stem Cells 
 
1. Adipose tissue 
2. Umbilical cord  
3. Bone marrow 
Treatment Cost 
$16,000 
Procedure/Protocol 
Administering the autologous stem cells back to the patient takes a minimum of seven steps: 
1. Liposuction to collect at least 100 to 300cc of fat from the patients abdomen or high thigh 
2. Breaking down and separation of the adipose tissue using a patented collagenase based solution 
3. Using a flow cytometer, the stromal vascular fraction (SVF) is separated 
4. Adult stem cells and progenitor cells are isolated from the SVF 
5. The adult stem cells are then cleaned/washed to remove any left over collagenase 
6. The isolated cells are suspended with the patient’s Platelet Rich Plasma (PRP) with other growth 
factors to activate the dormant cells 
7. Lastly, the stem cells are then injected back to the patient through intravenous drips. 
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7. China 
A. Name of Treatment center: Hope Medical Group/Stem Cells for Hope 
Stem cells for Hope Inc. has an international network of clinics around the world including China. This 
treatment center is offering stem cell treatment using autologous adult stem cells or from harvested Cord Blood 
Stem Cells. The Hope Treatment Center is a US based company, however, Stem Cell for Hope does not have 
any treatment facilities nor do they treat any patient inside the United States, however, applications for treatment 
can still be handled in the US, and then referred to a relevant treatment center outside the USA.  
Website 
http://www.hopestemcell.com 
Physical Address 
4474 Middle Country Road 
Calverton, NY 11933 
USA 
Tel: (631) 929- 3900 
Fax: (631) 929- 3909 
Email 
info@hopestemcell.com 
Diseases/Conditions Treated 
1. Multiple Sclerosis 
2. Parkinson’s Disease 
3. Stroke 
4. Macular Degeneration 
5. Optic nerve damage 
6. Optic Neuritis 
7. Liver cirrhosis 
8. Crohn’s Disease 
9. Hematopoietic stem cell transplantation 
10.  Cardiovascular and cerebrovascular diseases intervention therapy 
11. Other conditions are evaluated for treatment on a per case bases 
Sources of Stem Cells Used 
1. Cord Blood 
Treatment Cost 
Not provided 
Procedure/Protocol 
Umbilical Cord Stem Cells or Dendritic cells plus Cancer Killer Cells, and neurological approaches to treat a 
wide range of neurological disorders as well as cancer and other diseases. Scientists from National Institute of 
Health (NIH), instead of using surgery, chemotherapy or radiotherapy, are using CIK immunotherapy to attack 
tumors. CIK has proved in medical practice to be the most efficiently adopted immunotherapy. It shows good 
efficacies in treating malignant tumors in leukemia, melanoma, malignant lymphoma, renal cell carcinoma, 
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metastatic renal carcinoma, lung cancer and gastric cancer. 
8. Repair Stem Cell Institute (RSCI) 
RSCI is one of the largest Adult Stem Cell treatment institute with many treatment centers around the world, in 
countries like Argentina, Mexico, Thailand, Philipines, United States of America and many more. RSCI is using 
adult stem cell treatment to treat over 150 debilitating chronic conditions previously thought to be untreatable 
such as the ‘Big Three’ – Heart Disease, Diabetes and Lung Disease, as well as Ataxia, Parkinson’s Disease, 
Spinal Cord Injury, Cerebral Palsy, Multiple Sclerosis, Arthritis and Autism. More on RSCI centers in chapter 8. 
Website 
http://repairstemcells.org 
Physical Address 
Repair Stem Cells Institute 
3010 LBJ Freeway, Suite 1200 
Dallas, TX 75234 
Telephone  
(214) 556-6377 
Contact Person 
Don Margolis  
Email 
donmargolis@gmail.com 
Sources of Stem Cells used 
1. Umbilical Cord Blood 
2. Bone Marrow 
3. Adipose Tissue 
Treatment Cost 
Dependent upon the treatment center and the condition (s) being treated, otherwise, costs may be around 
$14,500 (see some treatment costs by treatment center in chapter 8). 
8. Stem Cell Treatment Centers recommended by Repair Stem Cell Institute (RSCI) 
The RSCI has worked tirelessly to find the top stem cell treatment centers worldwide. All centers recommended 
by RSCI and physicians meet the highest standards to ensure the safest and most effective therapy for their 
patients. 
All international stem cell treatment centers, physicians and supplying laboratories approved by RSCI must 
meet the following conditions; 
Treatment Centers: 
1. Must be licensed, certified and in good-standing with the country’s medical professional regulatory board. 
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2. Must have at least one year’s experience treating human patients with Repair Stem Cells, also known as 
Adult Stem Cells 
3. Must never have received a negative finding from a regulatory inquiry or governmental action concerning 
patient relations or marketplace fraud. 
4. Must use either the patient’s own stem cells or Cord Blood stem cells derived from the umbilical cords of 
newborn babies, including Umbilical Cord Blood stem cells derived from placentas of healthy newborns. In 
certain cases, cells from other donors, whether stem cells or plain cells may be used. RSCI will not 
recommend any center using fetal or embryonic stem cells to treat any disease. 
Physicians: 
1. Received honoraria or doctorates from at least two recognized academic institutions 
2. Participated in a successful Adult Stem Cell clinical trial 
3. Authored a published, peer-reviewed article on Repair Stem Cells 
4. Received a grant for Adult Stem Cell research from a government unit and /or a recognized charity/disease 
advocacy organization 
5. Presented a paper on stem cell treatment at a professional conference 
Laboratories producing ASC for RCSI stem cell treatment centers: 
1. Have a history of over 100 successful repair stem cell human implants 
2. Meet the minimum recognized Current Good Manufacturing Procedure (CGMP) standards. 
8.1 Stem Cell Treatment Centers recommended by RSCI include the following: 
1. Clinica San Nicholas in Buenos Aires, Argentina. The founder is Dr. Roberto Fernandez Vina. Dr. Vina is  
well known as the world’s number one stem cell cardiologist and diabetes stem cell specialist. Amongst a 
variety of diseases treated at the center, a six day stem cell treatment program for Diabetes, Lung and Heart 
Diseases is being offered at $14,900 including accommodation for the patient and companion. Some, just to 
mention a few of Dr. Vina’s numerous achievements include the first implant of stem cells during pump 
cardiac surgery, first trial of injection of stem cells directly into the heart, first implant of autologous stem 
cells in the pancreas to treat Diabetes 1 &2, first stem cell treatments for Chronic Obstructive Pulmonary 
Disease (COPD). 
2. Bioheart Company, a USA based company, this center has in April 2014  assembled doctors and specialists 
trained in stem cell treatments for a treatment study using autologous adult stem cells which was available 
to the general public. The study was a patient-sponsored research study for treatment of type 2 Diabetes. 
The treatment was available for only $5000. 
3.  The Philipines, Manila, Dr. Florencio Q. Lucero pioneered the use of Adipose or fat Adult Stem Cell 
Treatment for Diabetes in 2006. Dr. Lucero is a seasoned plastic surgeon with 34 years of private practice 
in Manila and in Dubai. To date, he has conducted clinical studies on 30 Diabetes patients and more than 
300 patients with various degenerative conditions, all of whom showed remarkable improvements in their 
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medical conditions.  Stem Cell Clinical Trials conducted includes the following; 
• The Efficacy safety of Autologous Fat Stem Cell Transplant in the management of type 1 and type 2 
Diabetes Mellitus 
• The Efficacy and safety of sheep placental Stem Cell activator in facial rejuvenation  
• Cosmetic application of platelet rich plasma as stem cell activator in facial rejuvenation 
4. Lauderdale, Florida, USA, the RSCI announced its new stem cell program for the treatment of Spinal Cord 
Injuries (SCI). The regenerative center is headed by Dr. Melvin M. Propis, a well known practitioner of 
stem cells science 
9. Conclusion  
Data collected for this publication is from 11 international Stem Cell Treatment Centers from 8 different 
countries. This information is enough to provide Stem Cell Treatment guidance to both physicians and patients 
alike because we were able to obtain contact details from each Treatment center. We were able to obtain costs 
for Stem Cell Treatment from each Treatment center with a list of medical conditions being treated, which is 
valuable information for patients to properly plan their financial commitments as they plan for their treatment. 
In our next publication we hope to include more treatment centers, especially from the USA, include 
testimonials of individuals with improved standard of life after obtaining a Stem Cell Treatment, we also hope 
to report on new developments in embryonic Stem Cell Research. 
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